Overcoming the hurdles
presented by inherited retinal disease

ATSENA is building a pipeline of first- and best-in-class gene therapies for inherited retinal diseases, conditions that cause progressive, irreversible vision loss and for which few or no approved treatments exist. Our programs include two late-stage clinical assets, two earlier-stage programs powered by our proprietary AAV technology platform, and multiple undisclosed discovery programs. ATSN-201 is now being tested in a pivotal Phase 3 trial for X-linked retinoschisis (XLRS), and ATSN-101 will be advanced toward a global pivotal trial for Leber congenital amaurosis type 1 (LCA1) in partnership with Nippon Shinyaku Co., Ltd later this year. ATSN-301 for Usher Syndrome Type 1B is advancing toward the clinic, and ATSN-401 for Stargardt disease is being tested in IND-enabling studies.